"beta-Alanine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
| Descriptor ID |
D015091
|
| MeSH Number(s) |
D12.125.042.070
|
| Concept/Terms |
beta-Alanine- beta-Alanine
- beta Alanine
- 3-Aminopropionic Acid
- 3 Aminopropionic Acid
|
Below are MeSH descriptors whose meaning is more general than "beta-Alanine".
Below are MeSH descriptors whose meaning is more specific than "beta-Alanine".
This graph shows the total number of publications written about "beta-Alanine" by people in this website by year, and whether "beta-Alanine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 8 | 2 | 10 |
| 2012 | 6 | 0 | 6 |
| 2013 | 8 | 1 | 9 |
| 2014 | 5 | 2 | 7 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta-Alanine" by people in Profiles.
-
Shiuey EJ, Mehran NA, Ustaoglu M, Zhang Q, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Lee D. The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes. Graefes Arch Clin Exp Ophthalmol. 2022 Mar; 260(3):967-974.
-
Syed ZA, Rapuano CJ. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease. Curr Opin Ophthalmol. 2021 May 01; 32(3):268-274.
-
Rapuano PB, Levin AV, Price JM, Myers JS, Lee D, Shukla AG. Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series. Ophthalmol Glaucoma. 2021 Mar-Apr; 4(2):232-234.
-
Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma. 2020 10; 29(10):878-884.
-
Lin MM, Moster SJ, Zheng CX, Anderson-Qui?ones CD, Katz LJ, Pro MJ, Myers JS, Moster MR, Lee D. Netarsudil's Effect in Eyes with a History of Selective Laser Trabeculoplasty. Ophthalmol Glaucoma. 2020 Jul - Aug; 3(4):306-308.
-
Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020 01; 34(1):72-88.
-
Sinha S, Lee D, Kolomeyer NN, Myers JS, Razeghinejad R. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2020 Jan; 21(1):39-45.
-
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". Circulation. 2014 Nov 25; 130(22):e195.
-
Ezekowitz MD, Kent AP. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. Circulation. 2014 Oct 21; 130(17):1505-14.
-
Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". Circulation. 2014 Sep 02; 130(10):e95.